Internal Medicine, Medical Oncology · Saint Louis, MO
NPI
1861814386
Since 2014
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
607 S New Ballas Rd, Suite 3425
Saint Louis, MO, 63141
Phone (314) 251-7057
Groups this clinician bills Medicare through
Medicare paid, 2024
$45K
823 services
Medicare patients, 2024
367
Average age 74
Drug cost, 2024
$4.5M
2,057 prescriptions
Company payments, 2025
$3,879
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bethany Sleckman was code 99213 (office e&m - established), 222 times for 164 patients. In total Bethany Sleckman billed 823 services in 13 codes, and Medicare paid $45K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-01-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 222 | 164 | $40.21 | $8,926 |
| 99214 Office E&M - Established | Office | 150 | 49 | $68.16 | $10K |
| 99212 Office E&M - Established | Office | 124 | 110 | $22.10 | $2,741 |
| 99214 Office E&M - Established | Facility | 58 | 14 | $69.78 | $4,047 |
| 99213 Office E&M - Established | Facility | 37 | 26 | $46.53 | $1,722 |
| 99232 Hospital E&M - Subsequent | Facility | 33 | 15 | $60.20 | $1,987 |
| 99215 Office E&M - Established | Office | 31 | 18 | $94.44 | $2,928 |
| 99223 Hospital E&M - Initial | Facility | 31 | 28 | $130.16 | $4,035 |
| 99231 Hospital E&M - Subsequent | Facility | 29 | 16 | $37.86 | $1,098 |
| 99212 Office E&M - Established | Facility | 22 | 22 | $24.57 | $541 |
| 99215 Office E&M - Established | Facility | 19 | 15 | $90.73 | $1,724 |
| 99204 Office E&M - New | Office | 13 | 13 | $102.61 | $1,334 |
By year: 2022 $62K for 730 services; 2023 $54K for 680 services; 2024 $45K for 823 services.
Medicare prescription drug claims, 2024
In 2024, the drug Bethany Sleckman prescribed most often to Medicare patients was Letrozole, with 639 prescriptions and refills. In total Bethany Sleckman wrote 2,057 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 639 | 1,788 | 195 | $15K |
| Tamoxifen Citrate Generic | 121 | 337 | 41 | $2,806 |
| Anastrozole Generic | 107 | 299 | 36 | $2,878 |
| Alendronate Sodium Generic | 81 | 206 | 25 | $599 |
| Ibrance Palbociclib | 77 | 77 | Under 11 | $1.2M |
| Hydroxyurea Generic | 71 | 125 | 16 | $1,739 |
| Gabapentin Generic | 61 | 75 | 19 | $912 |
| Eliquis Apixaban | 48 | 49 | Under 11 | $28K |
| Raloxifene Hcl Generic | 43 | 105 | 12 | $1,637 |
| Calquence Acalabrutinib Maleate | 36 | 36 | Under 11 | $414K |
| Revlimid Lenalidomide | 34 | 34 | Under 11 | $607K |
| Verzenio Abemaciclib | 34 | 34 | Under 11 | $527K |
| Lorazepam Generic | 31 | 35 | Under 11 | $115 |
| Ondansetron Odt Ondansetron | 30 | 31 | 14 | $574 |
| Xtandi Enzalutamide | 30 | 30 | Under 11 | $396K |
Brand drugs: 378 claims; generic drugs: 1,679 claims; opioid claims: 60.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bethany Sleckman $3,879 ($3,879 in general payments such as food, travel and fees) from 44 companies. The largest payer was Janssen Biotech, Inc. with $560.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 22 | $560 |
| Daiichi Sankyo Inc. 4568.T | 26 | $453 |
| Regeneron Healthcare Solutions, Inc. REGN | 7 | $297 |
| Merck Sharp & Dohme LLC MRK | 12 | $286 |
| E.R. Squibb & Sons, L.L.C. BMY | 14 | $252 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $198 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $147 |
| Abbvie Inc. ABBV | 10 | $142 |
| Gilead Sciences, Inc. GILD | 8 | $141 |
| BeOne Medicines USA, Inc. ONC | 5 | $134 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.